“The promise for patients has never been better from a scientific point of view,” said BIO CEO and former Member of Congress Jim Greenwood, speaking at the 22nd BIO CEO & Investor Conference in New York. “But it’s the worst of times politically.” Specifically: There are “mountains of political…

As the biotech industry advances scientific discovery around new tumor types and mechanisms of action, we’ve seen more than 2,000 combination trials launched to enhance PD-1/L1 checkpoint inhibitors’ effects on solid tumors. The oncology pipeline has some exciting new biotechnological approaches…

At the time this blog was published, the coronavirus had taken more than 500 lives across the globe and infected more than 28,000 people across 25 countries. While these numbers are alarming, hope is on the horizon – and America’s biopharmaceutical industry is leading the charge.  In a…

BIO’s Industry Analysis team has published its 5th report in a series on the innovation landscape of highly prevalent, chronic diseases. This new report [available here] reviews the state of drug development for hypertension and heart failure. As with the prior reports, the investigation into these…

The rapid spread of the coronavirus out of Wuhan, China has sparked concern across countries as the international community grapples with how best to contain it. The clock is ticking to find a solution. Luckily, innovative biotechnology companies are working tirelessly each today to heal the world…

Jennifer Bright with the Innovation and Value Initiative recently wrote for Morning Consult that the U.S. is “engaged in the challenging but important conversation about how to assess the value of pharmaceuticals.”  It’s a conversation that should be transparent and open to everyone,…

The 340B Drug Discount Program is in the spotlight with the release of a new report from the Government Accountability Office (GAO) calling attention to oversight of the program designed to help vulnerable patients gain access to affordable prescription drugs. As the findings show, the program,…

Rick Starrs, CEO of NAVREF When it comes to clinical research trials, America leads the world in providing patients with access to the latest, state-of-the-art care. However, an under-represented population in clinical studies might surprise you: veterans. To correct this shortfall,…

This week, Congress is expected to consider a USMCA trade agreement that does NOT include stronger IP protections for American innovators who develop biologic medicines. While the removal of these provisions is being hailed as a defeat for Big Pharma, here are three key points to keep in mind as…

By 2040, experts say the number of yearly cancer cases in Africa will double. In 2018 alone, cancer deaths in Africa (over 530,000) were 30 percent higher than deaths from malaria. Clearly, a shift in disease burdens has taken place on the continent. Biotechnology and pharmaceutical companies are…